Floatz logo

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Transient Ischemic Attack

Stanford UniversitySmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Transient Ischemic Attack cohort.

Asset / SponsorPhaseRating
Plavix
Sichuan Provincial People's Hospital
Phase 4BBB
Acetylsalicylic Acid
Sichuan Provincial People's Hospital
Phase 4BBB
Ticagrelor
Mazandaran University of Medical Sciences
Phase 3BBB
Apixaban
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Phase 4BBB
Rivaroxaban
General Hospital of Shenyang Military Region
Phase 4BBB

View all 42 →

Same molecule, other indications

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril is also rated in:

cerebral infarctionDormant
BBB
Indicative ·
79 / 100
View asset →
ischemic strokeDormant
BBB
Indicative ·
74 / 100
View asset →
Small Vessel Cerebrovascular DiseaseDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →